UCB S.A. (UNC.DU)
| Previous Close | 82.32 |
| Open | 82.12 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 82.12 - 82.88 |
| 52 Week Range | 75.02 - 115.75 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Here's Why Momentum in UCB SA (UCBJF) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, UCB SA (UCBJF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- Zacks
What Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"
UCB SA (UCBJF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- Reuters
UPDATE 2-U.S. FDA approves UCB's drug for rare childhood epilepsy
Belgian biotech firm UCB SA said on Monday the U.S. Food and Drug Administration (FDA) approved its drug to treat seizures associated with Lennox-Gastaut Syndrome (LGS), a rare form of childhood epilepsy. The drug, branded as Fintepla, already has the U.S. approval to treat another form of childhood-onset epilepsy, Davet Syndrome (DS), in patients aged two years and older.
